Neonatal Platelet Transfusion Threshold Trial

Launched by NICHD NEONATAL RESEARCH NETWORK · Nov 4, 2024

Keywords

ClinConnect Summary

The Neonatal Platelet Transfusion Threshold Trial, also known as the NeoPlaTT trial, is a study designed to find out if giving platelet transfusions at a lower level can help extremely preterm infants survive without serious bleeding. The trial focuses on infants born between 23 weeks and 26 weeks of gestation, and it aims to see if these babies do better with a lower threshold for transfusions compared to a higher one. This is important because it could improve their chances of survival as they grow.

To participate in this trial, infants must be between 0 to 48 hours old and born at the specified gestational age. However, if the baby is already receiving comfort care or has certain health conditions, they won’t be eligible. The trial is not yet recruiting participants, but families should know that it aims to improve care for very young infants with low platelet counts, which can lead to bleeding issues. Parents or guardians will need to provide consent for their child to join the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Gestational age of 23 0/7 to 26 6/7 weeks
• • Postnatal age of \< 48 hours
• Exclusion Criteria:
• • Comfort care or withdrawal of care planned
• • Neonatal alloimmune thrombocytopenia or suspected/confirmed congenital platelet or bleeding disorder
• • Receipt of platelet transfusion
• • No receipt of Vitamin K
• • Parents/guardian decline consent